(R)-N¹-(tert-butyl)-1-phenylethane-1,2-diamine | 926293-48-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (R)-N¹-(tert-butyl)-1-phenylethane-1,2-diamine
• 英文别名: [(2R)-2-amino-2-phenylethyl](tert-butyl)amine；(R)-N2-tert-butyl-1-phenylethane-1,2-diamine；(1R)-N'-tert-butyl-1-phenylethane-1,2-diamine
• CAS: 926293-48-3
• 化学式: C₁₂H₂₀N₂
• 分子量: 192.304
• InChiKey: AHSQQFCXXXKGLE-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-N¹-(tert-butyl)-1-phenylethane-1,2-diamine 在 三乙胺 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 2.58h， 生成 (4R,12R)-6,10-di(tert-butyl)-2-oxo-4,12-diphenyl-1λ⁵,3,6,10-tetraazatricyclo[7.3.0.0^3,7]dodeca-1(9),7-dien-1-ylium chloride
  参考文献：
  名称：

  亚甲基桥联双（咪唑啉）衍生的 2-氧代嘧啶盐作为不对称迈克尔反应的催化剂

  摘要：

  一言以蔽之：具有平面氮中心的标题盐被成功地用作甘氨酸叔丁酯二苯甲酮席夫碱与乙烯基酮和查尔酮衍生物的不对称迈克尔反应的相转移催化剂，从而提供了极好的非对映和对映控制水平（见方案）。

  DOI：

  10.1002/anie.201300614
• 作为产物：
  描述：

  左旋苯甘氨酸 在 N-甲基吗啉 、 硼烷四氢呋喃络合物 、 三氟乙酸 、 sodium hydroxide 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 二氯甲烷 、 叔丁醇 为溶剂， 反应 37.0h， 生成 (R)-N¹-(tert-butyl)-1-phenylethane-1,2-diamine
  参考文献：
  名称：

  Design of Substituted Imidazolidinylpiperidinylbenzoic Acids as Chemokine Receptor 5 Antagonists: Potent Inhibitors of R5 HIV-1 Replication

  摘要：

  The redesign of the previously reported thiophene-3-yl-methyl urea series, as a result of potential cardiotoxicity, was successfully accomplished, resulting in the identification of a novel potent series of CCR5 antagonists containing the imidazolidinylpiperidinyl scaffold. The main redesign criteria were to reduce the number of rotatable bonds and to maintain an acceptable lipophilicity to mitigate hERG inhibition. The structure activity relationship (SAR) that was developed was used to identify compounds with the best pharmacological profile to inhibit HIV-1. As a result, five advanced compounds, 6d, 6e, 6i, 6h, and 6k, were further evaluated for receptor selectivity, antiviral activity against CCR5 using (RS) HIV-1 clinical isolates, and in vitro and in vivo safety. On the basis of these results, 6d and 6h were selected for further development.

  DOI：

  10.1021/jm401101p

文献信息

• Synthesis of Novel Chiral (Thio)ureas and Their Application as Organocatalysts and Ligands in Asymmetric Synthesis
  作者：Marcos Hernández-Rodríguez、Claudia Gabriela Avila-Ortiz、Jorge M. del Campo、Delia Hernández-Romero、María J. Rosales-Hoz、Eusebio Juaristi

  DOI：10.1071/ch08116

  日期：——

  The synthesis of novel chiral (thio)ureas 1–10 and 14–26 is described. These (thio)ureas incorporate chiral auxiliaries derived from (R)- or (S)-α-phenylethylamine, (R)-phenylglycine, or (1R,2S)-ephedrine. The phenylethyl group in compounds 1–10 and 21–24 adopts a particular orientation in the molecular structure as a consequence of 1,3-allylic strain with the (thio)carbonyl group. Ureas 1–10 were

  描述了新型手性（硫）脲 1-10 和 14-26 的合成。这些（硫代）脲包含衍生自 (R)-或 (S)-α-苯乙胺、(R)-苯基甘氨酸或 (1R,2S)-麻黄碱的手性助剂。化合物 1-10 和 21-24 中的苯乙基在分子结构中采用特定的取向，这是由于 1,3-烯丙基应变与（硫代）羰基的结果。脲 1-10 作为路易斯碱性有机催化剂在环氧化物开环和醛缩合中进行了测试，发现四取代脲 (R,R)-2 在反应收率方面提供了最好的结果。（硫代）脲 20-26 作为对映选择性二乙基锌加成苯甲醛的配体进行了检测，观察到 C2 对称手性脲 (R,S,R,S)-20 以接近定量的产率和高达 62 的产率提供了预期的甲醇%对映体过量。
• Chemokine receptor binding compounds
  申请人：Zhou Yuanxi

  公开号：US20070066624A1

  公开（公告）日：2007-03-22

  The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

  本发明涉及化学因子受体结合化合物、药物组合物及其使用。更具体地，本发明涉及化学因子受体活性调节剂，优选地为CCR4或CCR5的调节剂。在一个方面，这些化合物表现出对人类免疫缺陷病毒（HIV）感染靶细胞的保护效应。
• WO2007/22371
  申请人：——

  公开号：——

  公开（公告）日：——
• Methylene-Bridged Bis(imidazoline)-Derived 2-Oxopyrimidinium Salts as Catalysts for Asymmetric Michael Reactions
  作者：Andrey E. Sheshenev、Ekaterina V. Boltukhina、Andrew J. P. White、King Kuok Mimi Hii

  DOI：10.1002/anie.201300614

  日期：2013.7.1

  In nothing flat: The title salts, having planar nitrogen centers, were utilized successfully as phase‐transfer catalysts for asymmetric Michael reactions of tert‐butyl glycinate benzophenone Schiff base with vinyl ketone and chalcone derivatives, thus providing excellent levels of diastereo‐ and enantiocontrol (see scheme).

  一言以蔽之：具有平面氮中心的标题盐被成功地用作甘氨酸叔丁酯二苯甲酮席夫碱与乙烯基酮和查尔酮衍生物的不对称迈克尔反应的相转移催化剂，从而提供了极好的非对映和对映控制水平（见方案）。
• Design of Substituted Imidazolidinylpiperidinylbenzoic Acids as Chemokine Receptor 5 Antagonists: Potent Inhibitors of R5 HIV-1 Replication
  作者：Renato Skerlj、Gary Bridger、Yuanxi Zhou、Elyse Bourque、Ernest McEachern、Markus Metz、Curtis Harwig、Tong-Shuang Li、Wen Yang、David Bogucki、Yongbao Zhu、Jonathan Langille、Duane Veale、Tuya Ba、Michael Bey、Ian Baird、Alan Kaller、Maria Krumpak、David Leitch、Michael Satori、Krystyna Vocadlo、Danielle Guay、Susan Nan、Helen Yee、Jason Crawford、Gang Chen、Trevor Wilson、Bryon Carpenter、David Gauthier、Ron MacFarland、Renee Mosi、Veronique Bodart、Rebecca Wong、Simon Fricker、Dominique Schols

  DOI：10.1021/jm401101p

  日期：2013.10.24

  The redesign of the previously reported thiophene-3-yl-methyl urea series, as a result of potential cardiotoxicity, was successfully accomplished, resulting in the identification of a novel potent series of CCR5 antagonists containing the imidazolidinylpiperidinyl scaffold. The main redesign criteria were to reduce the number of rotatable bonds and to maintain an acceptable lipophilicity to mitigate hERG inhibition. The structure activity relationship (SAR) that was developed was used to identify compounds with the best pharmacological profile to inhibit HIV-1. As a result, five advanced compounds, 6d, 6e, 6i, 6h, and 6k, were further evaluated for receptor selectivity, antiviral activity against CCR5 using (RS) HIV-1 clinical isolates, and in vitro and in vivo safety. On the basis of these results, 6d and 6h were selected for further development.